Behavioural brain research
May 8, 2025
Larissa da Silva Joaquim, Lara Rodrigues da Rosa, Yasmin Strickert et al.
5 citations
Ayahuasca, a decoction containing β-carbolines and DMT, reversed stroke-induced increases in the inflammatory markers IL-6, IL-10, and MPO activity in the prefrontal cortex and hippocampus of rats, and reduced oxidative stress markers TBARS in the prefrontal cortex and hippocampus. It also modulated mitochondrial enzyme activity in the hippocampus and cortex. However, ayahuasca did not improve neurological deficits, locomotion, anxiety-like behavior, or recognition memory. These molecular changes suggest a neuroprotective role against ischemia-induced neuroinflammation and oxidative stress, though without corresponding functional improvements in this three-day treatment study.
Frontiers in Molecular Biosciences
February 18, 2026
Gabriella de Souza Gomes Ribeiro, Beatriz Aparecida Passos Bismara Paranhos, Fabiane Dörr et al.
1 citation
Even modest increases in DMT exposure from ayahuasca may intensify serotonergic effects in individuals taking SSRI antidepressants, suggesting a clinically relevant interaction. The study provides a mechanistic and quantitative framework for assessing interaction risks between ayahuasca alkaloids and SSRIs, supporting clinical decision-making and harm-reduction strategies where controlled drug-drug interaction studies are not feasible.
Psychopharmacology
October 31, 2025
Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira et al.
Ayahuasca, a brew containing DMT and β-carbolines used in indigenous rituals, has shown potential for treating substance use disorders. In C57Bl/6 mice, ayahuasca at a high dose (15 mg DMT/kg) induced rewarding effects, but these were weaker than those of cocaine. When mice were conditioned with cocaine and later treated with ayahuasca (12.5 or 15 mg DMT/kg), the brew prevented the reinstatement of cocaine-induced conditioned place preference after a cocaine challenge. The findings suggest ayahuasca may have therapeutic value for cocaine use disorder by reducing relapse to drug-seeking behavior.
bioRxiv Preprint Server
May 7, 2024
Victor Distefano Wiltenburg, Gabriela Morales-Lima, Aline Valéria Sousa Santos et al.
preprint
Oral lyophilized ayahuasca, at doses equivalent to those used in traditional ceremonies, blocked the conditioned place preference (CPP) that mice normally develop for ethanol. In a CPP paradigm, mice pretreated with ayahuasca showed no preference for the ethanol-paired compartment (time difference within ±7 seconds), while controls showed a moderate preference (about +60 seconds). The effect was significant at all tested doses, and no differences were observed among ayahuasca groups. Ayahuasca was well tolerated at ceremony-equivalent doses, though the highest dose (5000 mg/kg) produced transient serotonergic-syndrome-like signs and locomotor deficits. ΔFosB expression in the nucleus accumbens did not differ among groups 24 hours after the post-test. The findings suggest ayahuasca may blunt ethanol-context preference, warranting replication with stronger reward baselines and additional molecular markers.
Psychopharmacology
October 1, 2022
Daiane Momo Daneluz, Jeferson Machado Batista Sohn, Gabriela O Silveira et al.
Ayahuasca, a psychedelic brew containing DMT and β-carbolines, impairs fear memory reconsolidation in rats when given 20 minutes before or 3 hours after memory retrieval. A dose of 60 mg/kg was effective at both time points and did not produce an anxiolytic effect. The impairment lasted at least 22 days with no spontaneous recovery or reinstatement of fear. The effect depended on memory retrieval; without retrieval, ayahuasca did not impair reconsolidation. These findings suggest ayahuasca disrupts both early and late stages of memory reconsolidation rather than facilitating fear extinction.